Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women

被引:5
|
作者
Cho, Hee Young [1 ]
Park, Han Sung [2 ]
Ahn, Eun Hee [3 ]
Ko, Eun Ju [2 ]
Park, Hyeon Woo [2 ]
Kim, Young Ran [3 ]
Kim, Ji Hyang [3 ]
Lee, Woo Sik [4 ]
Kim, Nam Keun [2 ]
机构
[1] CHA Univ, Dept Obstet & Gynecol, CHA Gangnam Med Ctr, Seoul 06135, South Korea
[2] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seongnam 13488, South Korea
[3] CHA Univ, Dept Obstet & Gynecol, CHA Bundang Med Ctr, Seongnam 13496, South Korea
[4] CHA Univ, Fertil Ctr, CHA Gangnam Med Ctr, Seoul 06135, South Korea
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 12期
基金
新加坡国家研究基金会;
关键词
plasminogen activator inhibitor-1; tissue plasminogen activator; renin; polymorphism; recurrent pregnancy loss; CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; T-PA; ANGIOTENSIN; RISK; INFLAMMATION; VARIANTS; RELEASE; SYSTEM; TYPE-1;
D O I
10.3390/jpm11121378
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recurrent pregnancy loss (RPL) is defined as two or more consecutive pregnancy losses prior to 20 weeks of gestational age. Various factors, including immune dysfunction, endocrine disorders, coagulation abnormality, and genetic disorders influence RPL. In particular, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), and renin (REN) have important roles in the thrombotic and thrombolytic systems, and abnormal expression of these genes have a reported negative correlation with pregnancy maintenance. Moreover, some polymorphisms of the three genes are related to expression levels and thrombotic disorder. Therefore, we investigated whether polymorphisms of PAI-1, tPA, and REN are linked to RPL. Genotyping of the six polymorphisms (PAI-1 rs11178, rs1050955, tPA rs4646972, rs2020918, REN rs1464816, and rs5707) was performed using polymerase chain reaction (PCR)-restriction fragment length polymorphism and associations of the polymorphisms with RPL were evaluated by statistical analysis. The polymorphism PAI-1 rs1050955 GA+AA was associated with decreased RPL risk (AOR, 0.528; 95% CI 0.356-0.781; p = 0.001) as was the REN 10795 rs5707 GG genotype (AOR, 0.487; 95% CI 0.301-0.787; p = 0.003). In contrast, the tPA rs4646972 II genotype correlated with increased RPL risk (AOR, 1.606; 95% CI, 1.047-2.463; p = 0.030). This study provides evidence that tPA Alu rs4646972 may contribute to the risk of idiopathic RPL, but PAI-1 12068 rs1050955 and REN 10795 rs5707 are associated with a decreased risk of RPL. Therefore, these alleles may be useful as biomarkers to evaluate the risk of RPL.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Assessment of Plasminogen Activator Inhibitor-1(PAI-1) Biomarker in Women with Breast Cancer Disease
    AL-Nafakh, Zahraa Mohammed
    AL-Dujaili, Arshad Noori G.
    Rudha, Ammar Rasoul Mohammed
    8TH INTERNATIONAL CONFERENCE ON APPLIED SCIENCE AND TECHNOLOGY (ICAST 2020), 2020, 2290
  • [12] Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
    Asselbergs, Folkert W.
    Pattin, Kristine
    Snieder, Harold
    Hillege, Hans L.
    van Gilst, Wiek H.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (06) : 562 - 568
  • [13] Effect of Tisseel® on expression of tissue plasminogen activator and plasminogen activator inhibitor-1
    Diamond, MP
    Kruger, M
    Saed, GM
    FERTILITY AND STERILITY, 2004, 81 (06) : 1657 - 1664
  • [14] EFFECT OF DEXTRAN ON PLASMA TISSUE-PLASMINOGEN ACTIVATOR (T-PA) AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) DURING SURGERY
    ERIKSSON, M
    SALDEEN, T
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1995, 39 (02) : 163 - 166
  • [15] Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator inhibitor-1)
    Chen, Fanglei
    Zhang, Guiping
    Hong, Zebin
    Lin, Zhonghui
    Lei, Min
    Huang, Mingdong
    Hu, Lihong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (10) : 2379 - 2382
  • [16] Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome
    Kulwas, Arleta
    Lisewska, Beata
    Jundzill, Wieslaw
    Ruszkowska, Barbara
    Drewniak, Wanda
    Ruprecht, Zofia
    Gadomska, Grazyna
    Rosc, Danuta
    ADVANCES IN MEDICAL SCIENCES, 2017, 62 (01): : 87 - 91
  • [17] Regulation of Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 by Hydrocortisone in Rat Primary Astrocytes
    Kwon, Kyoung Ja
    Cho, Kyu Suk
    Lee, Sung Hoon
    Kim, Jung Nam
    Joo, So Hyun
    Ryu, Jong Hoon
    Ignarro, Louis J.
    Han, Seol-Heui
    Shin, Chan Young
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (07) : 1059 - 1069
  • [18] Association between Plasminogen Activator Inhibitor-1 Gene Polymorphisms and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis
    Chen, Hui
    Nie, Shuping
    Lu, Ming
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2015, 73 (04) : 292 - 300
  • [19] Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility
    Hu, Xin
    Zan, Xin
    Xie, Zhiyi
    Li, Yunke
    Lin, Sen
    Li, Hao
    You, Chao
    MOLECULAR NEUROBIOLOGY, 2017, 54 (01) : 328 - 341
  • [20] Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes
    Brazionis, L.
    Yau, J.
    Rowley, K.
    Itsiopoulos, C.
    O'Dea, K.
    Wong, T. Y.
    Jenkins, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (02) : 192 - 199